千红制药：QHRD106已将相关资料递交CDE，待CDE审核通过后，即将有序进入三期临床

Core Insights - The company has confirmed that its new drug QHRD106 has progressed from Phase II to Phase III clinical trials, indicating a positive development in its drug pipeline [2] - For a drug to transition from Phase II to Phase III, it must demonstrate good safety and preliminary efficacy, and the relevant data along with the Phase III clinical plan must be submitted to the Center for Drug Evaluation (CDE) for approval [2] Company Information - QHRD106 has completed its Phase II clinical research and the related documentation has been submitted to the CDE, awaiting approval for orderly progression into Phase III clinical trials [2]